Pharma Pulse 1/31/25: What Round II of Medicare Part D Drug Prices Signify, 2025 Digital Healthcare Outlook & more

What Round II of Medicare Part D Drug Prices Signify for the Pharma Industry

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, value & access advisor for Schoonveld Advisory and author of The Price of Global Health, Ed Schoonveld, comments on the future implications of the latest CMS drug price negotiations.

2025 Digital Healthcare Outlook: Compliance, Security and Collaboration

Some regulatory changes are already set to happen this year, but reduced regulation under the new administration could have a ripple effects in healthcare. Meanwhile, artificial intelligence is likely to have pronounced impact on nonclinical workflows in 2025.

Takeda Picks First Woman as CEO of Centuries-Old Drugmaker

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Topography Health Survey Shows that Clinical Research Programs Boost Physician Engagement

Topography Health announced findings from a late 2024 survey, targeting US-based healthcare CFOs, COOs, and administrators who are actively managing clinical research programs around the clinical research experience of healthcare practices and systems.

Miranda Schmalfuhs on LinkedIn

You may have seen my multi-part video interview with Lawrence Werlin, MD, but there was more to our conversation that didn't make the final cut!

Check out some of those bonus insights in this brand new episode of the Pharmaceutical Executive podcast!

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs